Identification of the gene and mutation for progressive rod-cone degeneration in dog and a method for testing same

• US 20050282212A1
• Filed: 06/21/2005
• Published: 12/22/2005
• Est. Priority Date: 06/21/2004
• Status: Active Grant

• Current Assignee: Cornell Research Foundation Incorporated (Cornell University)
• Original Assignee: Cornell Research Foundation Incorporated (Cornell University)
• Inventors: Acland, Gregory M., Goldstein, Orly, Aguirre, Gustavo, Pearce-Kelling, Susan, Felix, Jeanette S., Zangerl, Barbara, Sidjanin, Duska J.
• Granted Patent: US 7,312,037 B2
• Time in Patent Office: Days
• US Class Current: 435/6.16
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers

Abstract

Tools and methods are provided for determining whether or not a dog is genetically normal, is a carrier of, or is affected with or predisposed to progressive rod-cone degeneration. The method is based on the detection of a transversion from G to A at position corresponding to nucleotide position 1298 of SEQ ID NO: 1.

Claims

1. A method for identifying a dog as genetically normal, as a carrier of, or as predisposed to progressive rod cone degeneration comprising:

a) obtaining a biological sample comprising nucleic acids from the dog; and

b) testing the biological sample comprising nucleic acids for a G to A transversion in the F04 gene at a position corresponding to nucleotide position 1298 of SEQ ID NO;

1, wherein the G to A transversion in one allele is indicative of a carrier of progressive rod-cone degeneration, the G to A transversion in both alleles is indicative of a dog affected with or predisposed to progressive rod-cone degeneration, and the absence of the G to A transversion is indicative of a genetically normal dog.

2. The method of claim 1, wherein the testing is carried out by amplifying the nucleic acids from the biological sample, digesting the amplified nucleic acids with one or more restriction endonucleases and identifying the G to A transversion in the amplified and digested nucleic acids.

3. The method of claim 2, wherein the amplification is carried out by polymerase chain reaction.

4. The method of claim 2, wherein the restriction endonuclease is RsaI.

5. The method of claim 2, wherein the restriction endonuclease is ApaLI.

6. The method of claim 3, wherein the nucleic acids are amplified by using primers of SEQ ID NO:

24 and SEQ ID NO;

25.

7. The method of claim 1, wherein the testing was carried out by pyrosequencing.

8. The method of claim 7, wherein pyrosequencing was carried out using primers of SEQ ID NOs. 20, 21 and 22.

9. The method of claim 1, wherein the nucleic acid is DNA.

10. The method of claim 1, wherein the nucleic acid is mRNA.

11. The method of claim 1, wherein the biological sample is any tissue containing genomic DNA or mRNA.

12. The method of claim 11, wherein the biological sample is selected from the group consisting of blood, hair, mucosal scrapings, semen, tissue biopsy and saliva

13. The method of claim 12, wherein the biological sample is blood.

14. The method of claim 1, wherein the dog is selected from the group consisting of akita, American cocker spaniel, American eskimos, Australian cattle dog, Australian stumpy tailed cattle dog, basenji, Bernase mountain dog, border collie, Chesapeake bay retriever, Chinese crested, English cocker spaniel, English mastiff, English springer spaniel, Entlebucher mountain dog, Finnish lapphund, German shorthaired pointer, giant schnauzer, Havanese, Labrador retrievers, lowchen, miniature poodle, miniature schnauzer, Nova scotia duck tolling retriever, Portuguese water dogs, samoyed, silky terrier, spitz, standard poodle, standard wirehaired dachshund, Tibetan terriers and toy poodle

15. An isolated polynucleotide comprising a DNA sequence of SEQ ID NO:

1, a RNA sequence corresponding to SEQ ID NO;

1, a DNA sequence complementary to SEQ ID NO;

1 or a RNA sequence complementary to SEQ ID NO;

1.

16. An isolated polynucleotide comprising a DNA sequence of SEQ ID NO:

3, a RNA sequence corresponding to SEQ ID NO;

3, a DNA sequence complementary to SEQ ID NO;

3 or a RNA sequence complementary to SEQ ID NO;

3.